TY - JOUR

T1 - Re

T2 - Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial

AU - Fode, Mikkel

AU - Jensen, Christian Fuglesang S.

AU - Sønksen, Jens

PY - 2024

Y1 - 2024

N2 - Masterson et al. [1] have presented the third randomized controlled trial (RCT) on platelet-rich-plasma (PRP) and erectile dysfunction (ED). Men with vasculogenic ED were assigned to intracavernosal PRP injections (n = 28) or placebo (n = 33). No significant differences were noted between the arms: 58.3%, 41.7%, and 60% of the PRP group, and 53.6%, 52%, and 41.7% of the placebo group met the minimal clinically important difference (MCID) for the International Index of Erectile Function-Erectile Function (IIEF-EF) scale at 1, 3, and 6 mo, respectively. The findings are in contrast to two previous RCTs and the inconsistencies necessitate a closer examination of the studies.

AB - Masterson et al. [1] have presented the third randomized controlled trial (RCT) on platelet-rich-plasma (PRP) and erectile dysfunction (ED). Men with vasculogenic ED were assigned to intracavernosal PRP injections (n = 28) or placebo (n = 33). No significant differences were noted between the arms: 58.3%, 41.7%, and 60% of the PRP group, and 53.6%, 52%, and 41.7% of the placebo group met the minimal clinically important difference (MCID) for the International Index of Erectile Function-Erectile Function (IIEF-EF) scale at 1, 3, and 6 mo, respectively. The findings are in contrast to two previous RCTs and the inconsistencies necessitate a closer examination of the studies.

U2 - 10.1016/j.eururo.2023.08.018

DO - 10.1016/j.eururo.2023.08.018

M3 - Comment/debate

C2 - 37696736

AN - SCOPUS:85170205287

VL - 85

SP - 93

JO - European Urology (Italian Edition)

JF - European Urology (Italian Edition)

SN - 1828-6569

IS - 1

ER -